Foghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026
Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909Â and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909Â and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer
Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026
NEVGOLD ANNOUNCES MINERAL RESOURCE: ANTIMONY OF 29,600 TONNES MEASURED & INDICATED AND 48,100 TONNES INFERRED ; 100% OXIDE GOLD OF 181,400 OZS MEASURED & INDICATED AND 1,203,500 OZS INFERRED; STRATEGIC U.S. ANTIMONY RESOURCE
SAGA Metals Reports Assays from R-0047 to R-0049 with Intercepts Including 53.72% Fe2O3, 7.32% TiO2, 0.431% V2O5 from 2026 Drilling at Trapper South, Radar Critical Minerals Project in Labrador
